Wei Ah und Zitiert - Info zur Person - Personensuche Yasni.de

(1 - 8 von 11

)

Azacitidine and Venetoclax in Previously Untreated Acute ...New England Journal of Medicine

www.nejm.org

von CD DiNardo · · Zitiert von: — DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020;135: Go to Citation. Crossref · PubMed · ISI. von CD DiNardo · · Zitiert von: — DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood 2020;135: Go to Citation. Crossref · PubMed · ISI.

Updated Safety and Efficacy of Venetoclax in Combination ...Genentech

medically.gene.com

von AH Wei · · Zitiert von: 5 — 2018;9(25):17270– Wei AH, et al. Blood ;135(24):2137–45. Scan QR code ... von AH Wei · · Zitiert von: 5 — 2018;9(25):17270– Wei AH, et al. Blood ;135(24):2137–45. Scan QR code ...

6-month follow-up of VIALE-C demonstrates improved and ...Nature

www.nature.com

von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ... von AH Wei · · Zitiert von: 24 — Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive ...

Alle Infos zum Namen "Wei Ah"

A Prospective Phase II Study (VALDAC)ASCO Publications

ascopubs.org

von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase von IS Tiong · · Zitiert von: 2 — Wei AH, Montesinos P, Ivanov V, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase

Chemotherapy and Venetoclax in Elderly Acute Myeloid ...ASCO Publications

ascopubs.org

von CC Chua · · Zitiert von: 134 — Wei AH, Strickland SA Jr, Hou J-Z, et al: Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia ... von CC Chua · · Zitiert von: 134 — Wei AH, Strickland SA Jr, Hou J-Z, et al: Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia ...

Oral Azacitidine (CC-486) for the Treatment of Myeloid ...Clinical Lymphoma, Myeloma and Leukemia

www.clinical-lymphoma-myeloma-leukemia.com

von G Garcia-Manero · · Zitiert von: 16 — 83. Roboz GJ, Ravandi F, Wei AH, et al. CC-486 prolongs survival for patients with Acute Myeloid Leukemia (AML) ... von G Garcia-Manero · · Zitiert von: 16 — 83. Roboz GJ, Ravandi F, Wei AH, et al. CC-486 prolongs survival for patients with Acute Myeloid Leukemia (AML) ...

Oral Azacitidine Maintenance Therapy for Acute Myeloid ...Europe PMC

europepmc.org

von AH Wei · · Zitiert von: 330 — Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. Wei AH 1 ,. Döhner H ... von AH Wei · · Zitiert von: 330 — Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. Wei AH 1 ,. Döhner H ...

subgroup analyses from the phase III QUAZAR AML Europe PMC

europepmc.org

von AH Wei · · Zitiert von: 1 — ... leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Wei AH 1 ,. Roboz GJ 2 ,. Dombret H von AH Wei · · Zitiert von: 1 — ... leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Wei AH 1 ,. Roboz GJ 2 ,. Dombret H

Verwandte Suchanfragen zu Wei Ah

Personen
Vorname "Wei" (618)
Name

sortiert nach Relevanz / Datum

Erweiterte Suche

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Wei Ah und Zitiert Person-Info